Key result
Pediatric hypertension affects approximately 3.6% of US children and is managed with lifestyle modifications and pharmacological therapies like ACE inhibitors to prevent long-term comorbidities.
This review summarizes the pathophysiology, diagnosis, and pharmacological treatment options for the growing population of children and adolescents with hypertension.
Highlights pediatric hypertension burden for clinicians; leaves open need for pediatric-specific outcome trials on ACE inhibitors.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lopilato et al. (2015) conducted a review in Pediatric Hypertension. Antihypertensive medications was evaluated. Pediatric hypertension affects approximately 3.6% of US children and is managed with lifestyle modifications and pharmacological therapies like ACE inhibitors to prevent long-term comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: